INBX
Inhibrx Biosciences, Inc.Inhibrx Biosciences, Inc. reported revenue of $1.30M in its most recent fiscal year, up 550.0% on the year before. It kept -10773.5% of that as net income, and generated -$129.82M of free cash flow. Figures below are compared against other companies classified under Biological Products, (No Diagnostic Substances).
Grades vs. industry
Growth
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Revenue growth (YoY) Latest fiscal year revenue vs. the year before. | 550.0% | 20.0% | — |
Revenue growth (3y) Annualized revenue growth over three fiscal years. | Not reported | 14.6% | — |
Revenue growth (5y) Annualized revenue growth over five fiscal years. | Not reported | 18.0% | — |
EPS growth (YoY) Diluted EPS vs. the prior fiscal year. | -108.0% | 53.1% | — |
EPS growth (3y) Annualized diluted EPS growth over three fiscal years. | Not reported | 5.5% | — |
EPS growth (5y) Annualized diluted EPS growth over five fiscal years. | Not reported | 5.4% | — |
Free cash flow growth (YoY) Operating cash flow less capital expenditure, vs. prior year. | Not reported | -24.7% | — |
Free cash flow growth (3y) Annualized free cash flow growth over three fiscal years. | Not reported | 6.8% | — |
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Nothing here is ranked: this company reported an operating loss several times its revenue, so it is left out of its industry’s comparisons and does not count toward the medians shown. Its own figures are exactly as filed.
Profitability
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Gross margin Gross profit as a share of revenue. Often unreported. | Not reported | 74.3% | — |
Operating margin Operating income as a share of revenue. | -10386.5% | -19.1% | — |
Net margin Net income as a share of revenue. | -10773.5% | -17.7% | — |
Free cash flow margin Free cash flow as a share of revenue. | -9986.5% | -22.3% | — |
Return on equity Net income divided by shareholder equity. | -1752.2% | -16.5% | — |
Return on assets Net income divided by total assets. | -95.6% | -8.0% | — |
Return on invested capital After-tax operating profit over debt plus equity less cash. | Not reported | -13.0% | — |
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Nothing here is ranked: this company reported an operating loss several times its revenue, so it is left out of its industry’s comparisons and does not count toward the medians shown. Its own figures are exactly as filed.
Financial health
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Debt to equity Total debt divided by shareholder equity. | 12.58x | 0.29x | — |
Current ratio Current assets over current liabilities. | 3.93x | 3.75x | — |
Quick ratio Current assets excluding inventory, over current liabilities. | 3.93x | 3.34x | — |
Interest coverage Operating income divided by interest expense. | -11.07x | 0.52x | — |
Net debt to EBITDA Net debt over derived EBITDA. EBITDA is not a GAAP tag; it is computed. | Not reported | -1.02x | — |
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Nothing here is ranked: this company reported an operating loss several times its revenue, so it is left out of its industry’s comparisons and does not count toward the medians shown. Its own figures are exactly as filed.
Debt figures can be understated where a filer splits borrowings across XBRL tags this site does not match.
Insider activity
Trades reported by officers, directors and 10% shareholders on SEC Form 4. 20 of the last 25 reported transactions were open-market purchases; the rest are mostly sales and compensation.
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 14, 2026 | Lappe Mark Chief Executive Officer | Open-market purchase | 2,470 | $85.00 | $209.9K |
| Oct 14, 2026 | Lappe Mark Chief Executive Officer | Open-market purchase | 2,451 | $85.00 | $208.3K |
| Oct 14, 2026 | Lappe Mark Chief Executive Officer | Open-market purchase | 2,470 | $84.07 | $207.7K |
| Oct 14, 2026 | Lappe Mark Chief Executive Officer | Open-market purchase | 2,449 | $84.07 | $205.9K |
| Oct 14, 2026 | Lappe Mark Chief Executive Officer | Open-market purchase | 100 | $85.76 | $8.6K |
| Oct 14, 2026 | Lappe Mark Chief Executive Officer | Open-market purchase | 100 | $85.76 | $8.6K |
| Sep 28, 2026 | Lappe Mark Chief Executive Officer | Open-market purchase | 3,000 | $101.70 | $305.1K |
| Sep 28, 2026 | Lappe Mark Chief Executive Officer | Open-market purchase | 1,500 | $98.88 | $148.3K |
| Sep 25, 2026 | Lappe Mark Chief Executive Officer | Open-market purchase | 3,324 | $98.87 | $328.6K |
| Sep 25, 2026 | Lappe Mark Chief Executive Officer | Open-market purchase | 2,176 | $99.60 | $216.7K |
| Sep 23, 2026 | Kayyem Jon Faiz Director | Open-market purchase | 5,000 | $100.00 | $500.0K |
| Sep 16, 2026 | Kayyem Jon Faiz Director | Open-market purchase | 5,000 | $100.00 | $500.0K |
| Sep 15, 2026 | MANHARD KIMBERLY Director | Open-market sale | 500 | $105.05 | $52.5K |
| Sep 14, 2026 | MANHARD KIMBERLY Director | Open-market sale | 500 | $110.26 | $55.1K |
| Sep 11, 2026 | MANHARD KIMBERLY Director | Open-market sale | 500 | $111.78 | $55.9K |
| Sep 9, 2026 | MANHARD KIMBERLY Director | Open-market sale | 500 | $115.80 | $57.9K |
| Sep 8, 2026 | Lappe Mark Chief Executive Officer | Open-market purchase | 9,681 | $112.28 | $1.09M |
| Sep 8, 2026 | Lappe Mark Chief Executive Officer | Open-market purchase | 6,605 | $100.64 | $664.7K |
| Sep 8, 2026 | Lappe Mark Chief Executive Officer | Open-market purchase | 5,895 | $99.29 | $585.3K |
| Sep 8, 2026 | Kayyem Jon Faiz Director | Open-market purchase | 5,000 | $113.52 | $567.6K |
| Sep 8, 2026 | FORSYTH DOUGLAS Director | Open-market purchase | 2,500 | $114.65 | $286.6K |
| Sep 8, 2026 | Lappe Mark Chief Executive Officer | Open-market purchase | 1,219 | $111.88 | $136.4K |
| Sep 8, 2026 | Lappe Mark Chief Executive Officer | Open-market purchase | 1,100 | $107.12 | $117.8K |
| Sep 8, 2026 | MANHARD KIMBERLY Director | Open-market sale | 500 | $115.14 | $57.6K |
| Sep 8, 2026 | Lappe Mark Chief Executive Officer | Open-market purchase | 500 | $108.23 | $54.1K |
A dash under price or value means none was reported, which is normal for grants and gifts — it does not mean the shares were free. Option exercises and awards are compensation arriving on a schedule, not a judgement about the stock.
Annual financials
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | $1.30M | $200.0K | $1.80M |
| Operating income | -$135.03M | -$331.45M | -$219.22M |
| Net income | -$140.06M | $1.69B | -$241.36M |
| EPS (diluted) | -$9.04 | $112.62 | -$20.48 |
| Operating cash flow | -$129.79M | -$194.41M | -$193.31M |
| Capital expenditure | $31.0K | $2.60M | $4.59M |
| Free cash flow | -$129.82M | -$197.01M | -$197.90M |
| Total assets | $146.48M | $180.77M | $307.89M |
| Shareholder equity | $7.99M | $133.58M | $43.50M |
| Total debt | $100.56M | $0.00 | $206.97M |
| Cash | $124.22M | $152.60M | $277.92M |
A dash means the figure was not tagged in that year’s filing. It does not mean zero. Figures reflect the most recent filing covering each period, so restated years show their restated values.
Source
Figures come from Inhibrx Biosciences, Inc.’s filings with the SEC, as submitted in XBRL. The most recent annual figures are from a 10-K filed Mar 19, 2026. View filings on EDGAR.